Tyrosine kinases are the targets of new treatments in oncology;Tyrosinkinasen als ziele neuer onkologischer therapien: Aussichten und probleme

Deutsches Arzteblatt

Volumn 104, Issue 19, 2007, Pages

  Müller Tidow, Carsten ^a   Krug, Utz ^a   Brunnberg, Uta ^a   Berdel, Wolfgang E ^a   Serve, Hubert ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Cancer therapy; Inhibitor of cell signals; Monoclonal antibody; Tyrosine kinase

Indexed keywords

3 [4 METHYL 2 (2 OXO 3 INDOLINYLMETHYLIDENYL) 3 PYRROLYL]PROPIONIC ACID; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CETUXIMAB; DASATINIB; DP 0173074; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; IMATINIB; IRINOTECAN; MIDOSTAURIN; PD 0173074; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; TRASTUZUMAB; UNCLASSIFIED DRUG; VANDETANIB; VASCULOTROPIN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; CANCER PATIENT; CANCER THERAPY; CHRONIC MYELOID LEUKEMIA; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL TRIAL; COLORECTAL CARCINOMA; DERMATOFIBROSARCOMA PROTUBERANS; DRUG EFFECT; DRUG EFFICACY; DRUG TARGETING; DRUG USE; ENZYME ACTIVATION; ENZYME INHIBITION; FIBROSARCOMA; GLIOBLASTOMA; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MEDICAL LITERATURE; MYELOPROLIFERATIVE DISORDER; PROGNOSIS; REVIEW; TREATMENT INDICATION; UNSPECIFIED SIDE EFFECT;

EID: 34447278806     PISSN: 00121207     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (25)

1. Robinson DR, Wu YM, Lin SF: The protein tyrosine kinase family of the human genome. Oncogene 2000; 19: 5548-57.
2. Emens LA, Davidson NE: Trastuzumab in breast cancer. Oncology (Williston Park) 2004; 18: 1117-28; discussion 31-2, 37-8.
3. Baselga J, Perez EA, Pienkowski T, Bell R: Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer Oncologist 2006; 11 (Suppl 1): 4-12.
4. Salomon DS, Brandt R, Ciardiello F, Normanno N: Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995; 19): 183-232.
5. Cunningham D, Humbiet Y, Siena S, et al.: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-45.
6. Poon RT, Fan ST, Wong J: Clinical implications of circulating angiogenic factors in cancer patients. J Clin Oncol 2001; 19: 1207-25.
7. Hurwitz H, Fehrenbacher L, Novotny W, et al.: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-42.
8. Yang JC, Haworth L, Sherry RM, et al.: A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003; 349: 427-34.
9. Sandler AB, Gray R, Brahmer J, et al.: Randomized phase II/III Trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC # 704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) Trial - E4599. J Clin Oncol 2005; ASCO Annual Meeting Proceedings Part I. 23(16S): abstract 4.
10. Miller KD: E2100: a phase III trial of paclitaxel versus paclitaxel/bevacizumab for metastatic breast cancer. Clin Breast Cancer 2003; 3: 421-2.
11. Buchdunger E, Cioffi CL, Law N, et al.: Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000; 295: 139-45.
12. O'Brien SG, Guilhot F, Larson RA, et al.: Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348): 994-1004.
13. Shah NP, Sawyers CL: Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias. Oncogene 2003; 22: 7389-95.
14. Talpaz M, Shah NP, Kantarjian H, et al.: Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006; 354: 2531-41.
15. Corless CL, Fletcher JA, Heinrich MC: Biology of gastrointestinal stromal tumors. J Clin Oncol 2004; 22: 3813-25.
16. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al.: Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353: 123-32.
17. Chan SK, Gullick WJ, Hill ME: Mutations of the epidermal growth factor receptor in non-small cell lung cancer - search and destroy. Eur J Cancer 2006; 42; 17-23.
18. Sandler AB: Nondermatologic adverse events associated with anti-EGFR therapy. Oncology (Williston Park) 2006; 20(5 Suppl 2): 35-40.
19. Motzer RJ, Hutson TE, Tomczak P, et al.: Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alfa (IFN-a) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol 2006; ASCO Annual Meeting Proceedings Part I. 24(18S): abstract LBA3.
20. New targeted therapy for rare stomach, kidney cancers. FDA Consum 2006; 40: 5.
21. Escudier B, Szczylik C, Eisen T, et al.: Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). J Clin Oncol 2005; ASCO Annual Meeting Proceedings Part I. 23(16S): abstract 4510.
22. Herbst RS, Johnson DH, Mininberg E, et al.: Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol 2005; 23: 2544-55.
23. Hainsworth JD, Sosman JA, Spigel DR, Edwards DL, Baughman C, Greco A: Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. J Clin Oncol 2005; 23: 7889-96.
24. Krause DS, Van Etten RA: Tyrosine kinases as targets for cancer therapy. N Engl J Med 2005; 353: 172-87.
25. Arteaga CL, Baselga J: Tyrosine kinase inhibitors: why does the current process of clinical development not apply to them? Cancer Cell 2004; 5: 525-31.